Inflammatory Intestinal Diseases最新文献

{"title":"Anti-IL 12/23 versus Anti-Tumor Necrosis Factor-α in Patients with Biologically Naïve Crohn's Disease: A Systematic Review and Meta-analysis.","authors":"Mohammad Al Hayek, Bisher Sawaf, Shahem Abbarh, Yusuf Hallak, Muaz Alsabbagh Alchirazi, Muhammed Elhadi, Dahham Alsoud, Anita Afzali, Miguel Regueiro","doi":"10.1159/000546858","DOIUrl":"10.1159/000546858","url":null,"abstract":"<p><strong>Introduction: </strong>Crohn's disease (CD) is a chronic inflammatory condition of the digestive tract, characterized by a noncontinuous pattern of transmural inflammation, leading to a significant decline in quality of life and productivity. For biologic-naïve patients, anti-tumor necrosis factor (TNF)-α and anti-interleukin (IL)-12/23 therapies are commonly recommended. This study compares anti-IL-12/23 and anti-TNF-α for clinical remission, corticosteroid-free remission, endoscopic remission, and endoscopic response in biologic-naïve patients.</p><p><strong>Methods: </strong>We searched PubMed, Google Scholar, VHL, Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized clinical trials and cohort studies. Data were analyzed using odds ratios (ORs) with 95% confidence intervals (CIs). A random-effects model was applied for meta-analysis.</p><p><strong>Results: </strong>Only 6 out of 5,401 articles were included, involving a total of 1,103 patients. Of these, 636 (57.6%) received anti-TNF-α therapy (infliximab or adalimumab), while 467 (42.4%) received anti-IL-12/23 (ustekinumab) therapy. Within 52 weeks, there were no statistically significant differences found between Ustekinumab and anti-TNF-α in terms of clinical remission (OR: 0.92, 95% CI: 0.55-1.54, <i>p</i> = 0.75), endoscopic remission (OR = 0.583, 95% CI: 0.289-1.176; <i>p</i> = 0.13), corticosteroid-free remission (OR: 1.19, 95% CI: 0.87-1.64, <i>p</i> = 0.28), or endoscopic response (OR = 0.48, 95% CI: 0.147-1.578; <i>p</i> = 0.23).</p><p><strong>Conclusion: </strong>This meta-analysis found no significant differences in clinical remission, corticosteroid-free remission, endoscopic remission, or endoscopic response within 52 weeks between ustekinumab and anti-TNF-α agents in biologic-naïve CD patients. However, due to study limitations, further high-quality, head-to-head trials are needed to refine treatment selection and optimize outcomes.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"169-179"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcome of Ciclosporin and Infliximab as Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis.","authors":"Florian Grob, Isabel Häberling, Gottfried Novacek, Andrea Kreienbühl, Luc Biedermann, Gerhard Rogler, Philipp Schreiner","doi":"10.1159/000546511","DOIUrl":"10.1159/000546511","url":null,"abstract":"<p><strong>Background: </strong>Ciclosporin and infliximab have equal short-term efficacy in treating acute severe ulcerative colitis (ASUC). However, data about long-term outcome and switching to a second rescue therapy are limited.</p><p><strong>Methods: </strong>Patients with steroid-refractory ASUC treated at a tertiary center in Switzerland were retrospectively analyzed regarding the outcome of different rescue therapies. Colectomy-free survival rates at 1, 3, and 5 years were estimated through Kaplan-Meier method. Furthermore, predictors of colectomy, the presence of adverse events at 1 year and mortality during the entire follow-up were assessed.</p><p><strong>Results: </strong>We analyzed a total of 46 patients who were treated initially with either ciclosporin (<i>n</i> = 31) or infliximab (<i>n</i> = 15) due to steroid-refractory ASUC between January 2010 and July 2021. A total of 13% patients received a second rescue therapy. In sum, 78%, 67%, and 48% were colectomy-free at 1, 3, and 5 years, respectively. Although there was a significant difference between the three arms in colectomy-free survival (<i>p</i> = 0.026), a post hoc analysis could not demonstrate a difference between each individual therapy compared to another. The post hoc analysis indicated a nonsignificant benefit with sequential therapy in comparison to ciclosporin (CsA) regarding the colectomy-free survival (<i>p</i> = 0.087). The outcome between infliximab and CsA was not statistically different (<i>p</i> = 0.149). The number of previous advanced therapies was negatively associated with 1-year colectomy-free survival (<i>p</i> = 0.049). Other variables such as age at hospitalization, sex, dose of steroids, disease duration, and albumin did not correlate with a higher risk of 1-year colectomy.</p><p><strong>Conclusions: </strong>This real-world single-center analysis confirms the equal efficacy and safety of infliximab and ciclosporin over a follow-up of 5 years. Patients not responding to the first may benefit of a second rescue therapy without increasing the risk of complication or mortality.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"155-160"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12193821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144496138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000546188","DOIUrl":"https://doi.org/10.1159/000546188","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000545081.].</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"125"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Perspective and Worry regarding Ulcerative Colitis-Associated Cancer: A Questionnaire-Based Surveillance Study.","authors":"Yosuke Shimodaira, Sho Fukuda, Tatsuki Yoshida, Kenta Watanabe, Tamotsu Matsuhashi, Kengo Onochi, Katsunori Iijima","doi":"10.1159/000546032","DOIUrl":"10.1159/000546032","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with ulcerative colitis are prone to mental disorders and may be under psychological burden due to the development of ulcerative colitis-associated cancer. Therefore, evidence regarding awareness and concerns about cancer development is needed. We aimed to investigate the state of awareness regarding cancer in patients with ulcerative colitis, and their concerns about cancer, awareness of risk factors, and information-gathering methods.</p><p><strong>Methods: </strong>Questionnaires were administered to patients with ulcerative colitis who regularly visited our hospital. The Cancer Worry Scale was used to quantitatively evaluate the anxiety of developing cancer and the psychological burden in daily life. The Inflammatory Bowel Disease Questionnaire and the Short Form-8 were used to evaluate quality of life. Factors associated with cancer risk were also investigated.</p><p><strong>Results: </strong>A total of 112 patients were included; 78 patients have perceived a risk of developing colorectal cancer. Cancer Worry Scale for colorectal cancer was significantly higher than that for gastric cancer. Of the patients who answered that they perceived developing colorectal cancer with ulcerative colitis, 70% found more details about developing cancer by asking doctors; and 85.7% by using the internet and social networking services. The intestinal disease-specific self-administered questionnaire, Inflammatory Bowel Disease Questionnaire, score was associated with positive Cancer Worry Scale. In the Short Form-8, a lower Mental Component Summary was also associated with a positive Cancer Worry Scale.</p><p><strong>Conclusion: </strong>Patients with ulcerative colitis can be affected by cancer worry. More scientific evidence, reliable information that patients can access, and accurate information conveyed by medical staff are required.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"161-168"},"PeriodicalIF":0.0,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Postoperative Pouch-Vaginal Fistula of Ulcerative Colitis Successfully Treated with Estriol Vaginal Tablet.","authors":"Yuhei Hashimoto, Fumikazu Koyama, Yosuke Iwasa, Tadataka Takagi, Kosuke Fujimoto, Takashi Tamura, Goki Ejiri, Chihiro Yoshikawa, Masayuki Sho","doi":"10.1159/000546361","DOIUrl":"10.1159/000546361","url":null,"abstract":"<p><strong>Introduction: </strong>Ileal pouch-vaginal fistula (PVF) is a severe complication that can occur following surgery for ulcerative colitis (UC). Most cases of PVF are managed surgically, and reports on successful closure through conservative treatment alone are limited. We report the first documented case of PVF closure without stoma formation, successfully treated with antibiotics and estriol vaginal tablets.</p><p><strong>Case presentation: </strong>A 65-year-old woman was diagnosed in her 50s with total colitis-type UC. She developed steroid-dependent, refractory disease, prompting the indication of infliximab therapy. However, infliximab failed to maintain remission, necessitating restorative proctocolectomy with ileal pouch-anal anastomosis followed by loop ileostomy. The postoperative course was uneventful, and the ileostomy was closed 6 months later. Two years after surgery, she developed fever, diarrhea, and vaginal discharge containing fecal fluid. The endoscopic evaluation identified a PVF secondary to pouchitis. She was admitted to the hospital, placed on fasting, and treated with antibiotics and estriol vaginal tablets. Endoscopy 18 days after initiating of estriol therapy revealed vaginal wall thickening and PVF closure, and she was subsequently discharged. Estriol vaginal tablet administration continued for 3 months, and no recurrence has been observed 9 years following surgery.</p><p><strong>Conclusion: </strong>Estriol vaginal tablets may be serve as an effective conservative treatment option for PVF following surgery for UC.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"151-154"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12173437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic Esophagitis Pathogenesis: All Clear?","authors":"Jan Hendrik Niess, Tanay Kaymak","doi":"10.1159/000546241","DOIUrl":"10.1159/000546241","url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic esophagitis (EoE) is a food- and aeroallergen-driven, type 2-mediated chronic inflammation that develops in genetically predisposed individuals with an impaired esophageal epithelial barrier. How pollutants, including detergents, the esophageal microbiome, immunity, and genetics trigger the multifaceted pathophysiology of EoE is not clear.</p><p><strong>Summary: </strong>This review summarizes and discusses recent findings concerning the possible contribution of the environment/exposome, the esophageal microbiome, genetics, immunity, and epithelial barrier integrity to developing esophageal type 2 inflammation and fibrosis in EoE. After summarizing the current literature, we formulate research questions that we consider relevant to EoE.</p><p><strong>Key messages: </strong>The anticipated progress in preclinical EoE animal models, primary cell culture technologies, sequencing technologies, and clinical trials, driven by academic research and the pharmaceutical industry, is poised to revolutionize our understanding of EoE. These advancements may uncover novel pathways that can be targeted for EoE treatment, inspiring hope for improved patient quality of life.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"135-150"},"PeriodicalIF":0.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic Esophagitis without Eosinophils: Do You Want to Mock Me?","authors":"Elena González de Béthencourt, Thomas Greuter","doi":"10.1159/000546069","DOIUrl":"10.1159/000546069","url":null,"abstract":"<p><strong>Background: </strong>Eosinophils and eosinophil infiltration are the hallmark for the diagnosis of eosinophilic esophagitis (EoE), which represents the most common cause of solid food dysphagia in young adults. However, the role of eosinophils in the pathogenesis of EoE has been increasingly questioned.</p><p><strong>Summary: </strong>It is now well accepted that EoE is a Th2-mediated disorder with a myriad of inflammatory processes being involved rather than a single cell disease. In recent years, several nuances of EoE, so-called EoE variants, have been described, among which are EoE-like esophagitis, nonspecific esophagitis, lymphocytic esophagitis, and potentially also mast-cell esophagitis. These variants appear to have distinct molecular fingerprints sharing pronounced traits of EoE. Of note, there is a considerable flux between the variants (with frequent transitions) and eventual progression to EoE over time. Thus, EoE variants and EoE appear to be a spectrum disorder, where EoE only represents the most extreme phenotype.</p><p><strong>Key messages: </strong>This review summarizes current knowledge about these different variants and discusses future directions and open questions.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"126-134"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Concentration of Calprotectin, but Not Serum Concentration, Is a Predictive Biomarker for Clinical Remission in Ulcerative Colitis.","authors":"Sailish Honap, Isabelle Aimone-Gastin, Sylvain Salignac, Justine Flayac, Justine Paoli, Laurent Peyrin-Biroulet, Abderrahim Oussalah","doi":"10.1159/000545722","DOIUrl":"10.1159/000545722","url":null,"abstract":"<p><strong>Introduction: </strong>Fecal calprotectin is a validated biomarker for assessing disease activity in patients with inflammatory bowel disease (IBD). Blood calprotectin concentrations are correlated with disease activity in numerous immune-mediated inflammatory diseases. The aim of this study was to prospectively assess the diagnostic accuracy of plasma calprotectin as a potential biomarker of remission in IBD patients.</p><p><strong>Methods: </strong>This prospective observational study enrolled 131 patients at the time of infliximab administration alongside clinical assessment and blood analyses on the same day. The primary endpoint was to assess the diagnostic accuracy of plasma calprotectin for predicting remission in patients with IBD.</p><p><strong>Results: </strong>Plasma calprotectin concentration ≤10.5 ng/mL had a sensitivity of 98.6%, specificity of 100%, positive predictive value of 100%, negative predictive value of 96.3%, and an area under the receiver operating characteristic (AUROC) curve of 0.999 for diagnosing remission in patients with ulcerative colitis (UC). Plasma calprotectin had poor diagnostic accuracy for diagnosing remission in Crohn's disease. In UC, plasma calprotectin had significantly greater diagnostic accuracy than C-reactive protein for diagnosing remission (absolute difference between AUROCs, 0.06; 95% CI: 0.008 to 0.113; <i>p</i> = 0.03). Plasma calprotectin concentrations were not correlated with those measured in serum samples. The median serum-to-plasma calprotectin concentration ratio was 12-fold.</p><p><strong>Conclusion: </strong>Plasma calprotectin is a promising biomarker for predicting remission in UC patients treated with infliximab.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"104-114"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the Clinical Remission Course in Ulcerative Colitis from Tofacitinib Induction to Tapering or Withdrawal in Japanese Patients: A Single-Center Retrospective Study.","authors":"Miki Koroku, Teppei Omori, Shun Murasugi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige, Yousuke Nakai","doi":"10.1159/000545704","DOIUrl":"10.1159/000545704","url":null,"abstract":"<p><strong>Introduction: </strong>Tofacitinib (TOF), a Janus kinase inhibitor, has emerged as an innovative treatment option for patients with moderate-to-severe ulcerative colitis (UC). However, the clinical course of patients who achieve induction and maintain remission followed by TOF tapering or withdrawal is unclear. We investigated the efficacy of TOF and the clinical course after TOF tapering or withdrawal in real-world clinical practice.</p><p><strong>Method: </strong>Thirty-two patients treated with TOF 20 mg/day for UC relapse between October 2018 and August 2023 were included in this single-center, retrospective observational study. Disease activity was defined by partial Mayo score (PMS), and remission was defined as PMS ≤2 and rectal bleeding score 0, other score ≤1. PMS before TOF 20 mg/day induction was compared with PMS at 8 weeks. Patients who achieved clinical remission were tapered to 10 mg/day, while those who requested for drug withdrawal were allowed. The relapse rate of the TOF 10 mg/day maintenance group and the TOF withdrawal group was compared. Both groups included patients who had maintained remission at 6 months after tapering TOF to 10 mg/day. In addition, the efficacy of TOF 20 mg/day reinduction therapy was also compared between patients who relapsed in the TOF 10 mg/day maintenance group and the TOF withdrawal group.</p><p><strong>Result: </strong>Twenty-three patients (71.9%) achieved induction of remission by 8 weeks after TOF 20 mg/day administration, with significantly lower PMS than before TOF (<i>p</i> < 0.0001). Ultimately, 27 patients (84.4%) achieved remission, 24 who achieved remission were tapered to 10 mg/day, whereas 18 were able to maintain remission for 6 months. Seven of the 18 eventually withdrew from TOF. There was no significant difference in relapse rates between the TOF 10 mg/day maintenance group (<i>n</i> = 11; follow-up, 525 [29-1,483] days) and the TOF withdrawal group (<i>n</i> = 7; follow-up, 284 [77-797] days) (5/11 [45.5%] vs. 3/7 [42.9%], log-rank test: <i>p</i> = 0.7091). All patients who received TOF 20 mg/day reintroduction therapy after relapse went into remission.</p><p><strong>Conclusion: </strong>In clinical practice, TOF 20 mg/day significantly induced induction of remission, and in patients who received 6 months of maintenance remission therapy with TOF 10 mg/day, the relapse rates between the TOF 10 mg/day maintenance group and the TOF withdrawal group were similar. After relapse, TOF 20 mg/day reintroduction therapy improved symptoms.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"115-124"},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fatigue Is Strongly Associated with Depressive Symptoms in Patients with Inflammatory Bowel Disease.","authors":"Robin Mona, Andreas Göldi, Tobias Schneider, Isabelle Panne, Andrea Egger, Jan Hendrik Niess, Petr Hrúz","doi":"10.1159/000545572","DOIUrl":"https://doi.org/10.1159/000545572","url":null,"abstract":"<p><strong>Introduction: </strong>Fatigue is an extraintestinal manifestation in patients with inflammatory bowel disease (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), with limited information on the underlying factors. This study aimed to determine the prevalence of fatigue and associated factors in IBD patients.</p><p><strong>Methods: </strong>This prospective observational study assessed 216 IBD patients treated with intravenous infliximab or vedolizumab. Clinically meaningful fatigue was defined using a visual analog scale with a score ≥4 (VAS-F, range 0-10). Further assessments included the patient health questionnaire (PHQ-8) for depressive symptoms, the IBD-control-8 questionnaire to evaluate subjective disease control and the fatigue impact scale (FIS) for patients' quality of life (QoL). Demographic, clinical and laboratory data of the study population were collected and compared to identify fatigue-associated factors.</p><p><strong>Results: </strong>Overall, 53.2% (<i>n</i> = 115) of the IBD patients reported clinically meaningful fatigue with a higher prevalence in UC (63.0%) versus CD (47.4%). Among patients with CD, disease activity was significantly associated with fatigue symptoms (<i>p</i> < 0.001), whereas no such correlation was observed in UC patients (<i>p</i> = 0.85). Clinically meaningful fatigue symptoms were reported in 90.9% of patients with depressive symptoms (PHQ-8 ≥10). Furthermore, patients with fatigue were younger (40 vs. 42 years, <i>p</i> = 0.04), reported more frequent use of concomitant psychoactive and/or sedative medication (<i>p</i> = 0.03) and had lower IBD-control-8 scores (median 12 vs. 16 points, <i>p</i> < 0.001). Only minor differences were observed when comparing serum and fecal laboratory values of patients with fatigue symptoms to those without.</p><p><strong>Conclusion: </strong>Fatigue is highly prevalent among IBD patients treated with vedolizumab or infliximab and has a substantial impact on patients' QoL. Fatigue and depressive symptoms were strongly associated, suggesting closer monitoring for depression and the use of psychoactive medication in patients with IBD.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"90-103"},"PeriodicalIF":0.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}